Interested to learn about circulating calprotectin at ADLM 2024?

Circulating calprotectin - S100A8/A9 heterodimer in inflammation

Calprotectin in plasma and serum - a sensitive and early biomarker in detection and assessment of inflammation. If you want to learn more about this novel biomarker, please visit Gentian Diagnostic at booth #3210.

Learn about the novel biomarker at ADLM

Sensitive and early detection of inflammation

Calprotectin, a heterodimer composed of two calcium-binding proteins (S100A8/A9 or MRP8/14), is part of the S100 protein family and is abundantly expressed by white blood cells, particularly neutrophils. Large amounts of stored calprotectin are released from neutrophils during inflammation. This direct and fast upregulation in inflammation makes calprotectin a highly sensitive and early biomarker. The concentrations of circulating calprotectin correspond to the degree of inflammation. Indications for its use have been reported in both infectious and non-infectious inflammatory conditions.¹

Value of calprotectin in infections

Calprotectin is released in the first-line defence during infection and levels rise within only a few hours after infection. This direct and fast response makes calprotectin an ideal biomarker for the inflammatory response to infections.^2,3

• Detection and differentiation of bacterial infections
• Assess and predict severity of infections
• Follow disease activity and treatment response
• Detect and predict relapse in remission
  
  

Value of calprotectin in Rheumatology

Calprotectin is emerging as valuable biomarker in several chronic inflammatory conditions, including rheumatic diseases like Rheumatoid Arthritis, Juvenile Idiopathic Arthritis and Still’s Disease. Locally released calprotectin enters the systemic circulation where it can be measured in serum and plasma, at levels proportional to joint inflammatory activity.^4,5

• Direct marker of inflammatory activity
• Detect low grade and subclinical inflammation activity
• Monitoring of treatment and remission
• Risk marker for disease flares
  
  

Posters focusing on calprotectin in blood at ADLM 2024

B-068. Plasma calprotectin as an index of draining tunnel formation in Hidradenitis suppurativa

1: Gentian AS, Moss, Norway, 2: 24th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

Calprotectin is presented, for the first time, as a biomarker which indicates the formation of dTs in the skin. Its use as surrogate of early start of biologicals and response to treatment remains to be explored.

Please visit us at the poster sessions: 1:30 to 2:30 pm Wednesday July 31

A-307. Clinical utility of serum calprotectin in febrile infants presenting to the Emergency Department

1: University of Toronto, Toronto, ON, Canada, 2: Gentian, Moss, Norway, 3: Uppsala University, Uppsala, Sweden, 4: The Hospital for Sick Children, Toronto, ON, Canada

Calprotectin is reported to identify bacterial infection in febrile infants presenting to the Emergency Department (ED) relative to other common biomarkers of infection.

Please visit the poster sessions to talk to the author: 1:30 to 2:30 pm Tuesday July 30

Gentian Calprotectin GCAL® Immunoassay* 

GCAL^® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) rapidly performed in only 10 minutes. As open channel assay it is available on a wide range of clinical chemistry platforms.

The assay is not cleared for use in the USA. The assay is IVDR certified.

Get in touch with Gentian

Interested in plasma and serum calprotectin? Want to know more? Meet us at booth #3210 at ADLM 2024. Book a meeting by sending an email to marketing@gentian.com or fill out the form below:

References:

1. Pruenster M et al. S100A8/A9: From basic science to clinical application. Pharmacol Ther. 2016
2. Fullerton J et al. 40th International Symposium on Intensive Care & Emergency Medicine. Critical Care, 2020
3. Havelka A et al. Calprotectin, a new biomarker for diagnosis of acute respiratory infections. Scientific reports, 2020
4. Wang Q et al. The Role of Calprotectin in Rheumatoid Arthritis. J Transl Int Med. 2019
5. Ometto F et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 2017

* Gentian's plasma and serum calprotectin immunoassay is not cleared for use in the USA.

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.